High dose therapy (HDT) supported with autologous stem cell transplantation has become a standard way to manage aggressive myeloma. However, after single or double transplantation, almost all patients ultimately relapse. New strategies are required to control any residual disease after HDT, including maintenance treatment with thalidomide and pamidronate.
Go to Previous Page
Go to Next Page